Clinical trials: Cancer Progression
Chronic Kidney Diseases
Sex Differences in Chronic Kidney Disease
This study aims to describe sex specific differences of the hemodialysis population in Austria, to quantify sex specific differences in treatment and outcomes in hospitalized patients with chronic kidney disease and to examine…
- Trial name
- NCT03771703
- Where
- Austria
- Volunteers
- 1,100 people
- Sponsor
- Assoc. Prof. Dr. Manfred Hecking, MD PhD
Degenerative Disc Disease, Protrusion
Stabilizing Training in Degenerative Disc Disease
This study evaluates efficacy of stabilizing training of deep core muscles in the lumbar spine in degenerative disc disease subjects, considering the progression level of degenerative disc disease: protrusion or extrusion.
- Conditions
- Degenerative Disc Disease, Protrusion, Extrusion of Migrated Disc, Hernia
- Trial name
- NCT04119466
- Testing
- Stabilizing training
- Where
- Poland
- Volunteers
- 38 people
- Sponsor
- Wroclaw University of Health and Sport Sciences
Macular Holes
Preoperative Progression of Macular Holes
Knowledge of the natural history and progression of macular holes is mainly limited to the studies from the pre-optical coherence tomography era.
- Trial name
- NCT02203929
- Where
- Denmark
- Volunteers
- 37 people
- Sponsor
- Glostrup University Hospital, Copenhagen
HER2-positive Breast Cancer, Early Breast Cancer (EBC)
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage…
- Trial name
- NCT07856303
- Testing
- SHR-A1811, Trastuzumab, Pertuzumab
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Fudan University
First Progression of MGMT Promoter-methylated Glioblastoma
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated.
- Trial name
- RIGOLETTO (NCT04933942)
- Testing
- Lomustine, Romiplostim
- Where
- 5 sites in Spain, Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Malignancies, Pseudoprogression
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).
- Trial name
- NCT06199479
- Testing
- MRI Scan, CT Scan, Biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy.
- Conditions
- Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Trial name
- NCT05616624
- Testing
- ADI-PEG 20, Gemcitabine, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis Lung
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M.
- Trial name
- BioMol-MA (NCT06413459)
- Testing
- Luminex; scRNAsec
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele
Prostate Carcinoma
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
- Trial name
- NCT04597359
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Where
- 353 sites in United States, Guam and 1 more
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
NSCLC, Stage I, II, IIIA, IIIB, Surgery
Pronostic and Predictive Value of EMT in Localized Lung Cancer
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC.
- Conditions
- NSCLC, Stage I, II, IIIA, IIIB, Surgery, Progression, Epithelial Mesenchymal Transition
- Trial name
- TWISTlung (NCT03509779)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- European Georges Pompidou Hospital
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases
- Trial name
- NABPLAGEMD (NCT03415854)
- Testing
- Paricalcitol (Zemplar)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- HonorHealth Research Institute
Coronavirus Disease 2019 )COVID-19)
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.
Older age is an independent poor outcome predictor among COVID-19 hospitalized patients . Among 72,314 COVID-19 cases, case fatality rate (CFR) was 2.3% in total population, 8% in people aged 70 to 79, and 14.8% in those aged 80…
- Trial name
- LIFESAVER (NCT04374526)
- Testing
- COVID-19 Convalescent Plasma
- Where
- 3 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fibrous Dysplasia
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
Background: Fibrous dysplasia (FD) is a disease that affects the bones. It causes bone lesions that can become weak and lead to fractures, deformity, and nerve injuries.
- Trial name
- NCT05419050
- Testing
- denosumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Asthma, Vitamin D Deficiency
Vitamin D Deficiency and Asthma Exacerbation
The study aim is in two phases. First phase: to evaluate the influence of vitamin D deficiency on asthma severity, degree of airway obstruction and frequency of asthma exacerbations.
- Conditions
- Asthma, Vitamin D Deficiency, Disease Exacerbation
- Trial name
- AVD (NCT02661191)
- Testing
- oral cholecalciferol
- Volunteers
- 119 people
- Sponsor
- University of Turin, Italy
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Breast Cancer, Ovarian Cancer
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for…
- Conditions
- Breast Cancer, Ovarian Cancer, Breast Neoplasms, Ovarian Neoplasms
- Trial name
- NCT05904730
- Testing
- Axitinib
- Where
- 2 sites in Ukraine
- Volunteers
- 10 people
- Sponsor
- Lynkcell Europe
IPMN, IPMN, Pancreatic
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
- Trial name
- NCT04207944
- Testing
- Sulindac 400 MG
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Prostate Cancer
Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.
Prostate cancer biochemical recurrence (BCR) occurs in 20-50% of patients following radical prostatectomy or radiotherapy. Due to significant risk of side effects and uncertainty about the benefits, physicians and patients are…
- Trial name
- RCT-EPAII-BCR (NCT03753334)
- Testing
- MAG-EPA
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- CHU de Quebec-Universite Laval
Follicular Lymphoma
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.
- Trial name
- NCT03525665
- Testing
- Metabolic activity measured by FDG-PET
- Where
- 27 sites in Italy
- Volunteers
- 175 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.